Dexmedetomidine and Delirium in Patients After Cardiac Surgery
Delirium, C.Surgical Procedure; Cardiac, Postoperative Complications
About this trial
This is an interventional prevention trial for Delirium focused on measuring Delirium, Cardiac Surgical Procedures, Postoperative Complications, Dexmedetomidine, Prevention
Eligibility Criteria
Inclusion Criteria:
Patients of 60 years or older who are planning to receive cardiac surgery (CABG and/or valve replacement surgery)
Exclusion Criteria:
Patients will be excluded if they meet any of the following criteria:
- Refuse to participate;
- Preoperative history of schizophrenia, epilepsia, Parkinson syndrome, or severe dementia;
- Inability to communicate in the preoperative period because of severe visual/auditory dysfunction or language barrier;
- History of brain injury or neurosurgery;
- Preoperative sick sinus syndrome, severe bradycardia (HR < 50 bpm), second-degree or above atrioventricular block without pacemaker;
- Severe hepatic dysfunction (Child-Pugh class C);
- Severe renal dysfunction (requirement of renal replacement therapy);
- Other conditions that are considered unsuitable for participation.
Sites / Locations
- Peking University First Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Dex group
Placebo group
The intervention drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
The placebo drug (normal saline, i.e., 0.9% sodium chloride for injection) will be administered in the same way and rate for a same duration as that in the Dex group.